Overall, 20% of patients with major depressive disorder (MDD) are treatment-resistant and do not respond to multiple antidepressant monotherapies. For such patients, augmentation therapy with antipsychotics is one of the therapeutic options. However, the mechanism of augmentation therapy is essentially unknown.
Aim:
This study aimed to elucidate the mechanism of brexpiprazole (BREX) augmentation at gene expression levels.
Methods:
Vehicle, escitalopram (ES), BREX, and ES + BREX (augmentation therapy) were administered to mouse neuroblastoma (Neuro2a) cells and submitted to RNA-sequencing. Gene expressions were also measured in the whole blood of MDD patients and the frontal cortices and hippocampi of mice after treatment for 20 days.
Results:
On RNA-seq and gene ontology analyses, upregulation of mitochondria (MT)-related genes was confirmed by quantitative Polymerase Chain Reaction (PCR). These upregulated genes were successfully validated in both Neuro2a and Caco2 cells. Decreased MT-ATP8 expression was found in the whole blood of MDD patients. Furthermore, changes in MT-mRNA expression were confirmed in the frontal cortices and hippocampi of mice with augmentation therapy.
Conclusions:
BREX augmentation modified MT-mRNA expressions in both in vitro and in vivo experiments. This may be a key finding in improving our understanding of MDD pathogenesis and clinical practice.
AllenJRomay-TallonRBrymerKJ, et al. (2018) Mitochondria and mood: Mitochondrial dysfunction as a key player in the manifestation of depression. Front Neurosci12: 386.
2.
AmadaNHiroseTSuzukiM, et al. (2023) Synergistic anti-depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice. Neuropsychopharmacol Rep43: 132–136.
3.
AnglinREGarsideSLTarnopolskyMA, et al. (2012) The psychiatric manifestations of mitochondrial disorders: A case and review of the literature. J Clin Psychiatry73: 506–512.
4.
BindeaGMlecnikBHacklH, et al. (2009) ClueGO: A Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics25: 1091–1093.
5.
CarterBStrawbridgeRHusainMI, et al. (2020) Relative effectiveness of augmentation treatments for treatment-resistant depression: A systematic review and network meta-analysis. Int Rev Psychiatry32: 477–490.
6.
ChenVCHuangJYTzangBS, et al. (2022) Synergistic effects of the combinational use of escitalopram oxalate and 5-fluorouracil on the inhibition of gastric cancer SNU-1 cells. Int J Mol Sci23: 16179.
7.
CuiXXuYZhuH, et al. (2023) Long noncoding RNA NONHSAG045500 regulates serotonin transporter to ameliorate depressive-like behavior via the cAMP-PKA-CREB signaling pathway in a model of perinatal depression. J Matern Fetal Neonatal Med36: 2183468.
8.
FattalOLinkJQuinnK, et al. (2007) Psychiatric comorbidity in 36 adults with mitochondrial cytopathies. CNS Spectr12: 429–438.
9.
FurukawaYOguroSObataS, et al. (2022) Optimal dose of brexpiprazole for augmentation therapy of antidepressant-refractory depression: A systematic review and dose-effect meta-analysis. Psychiatry Clin Neurosci76: 416–422.
10.
GammohOQnaisEYAthamnehRY, et al. (2023) Unraveling the potential of isorhamnetin as an adjuvant in depression treatment with escitalopram. Curr Issues Mol Biol45: 7668–7679.
11.
GlombikKStachowiczATrojanE, et al. (2017) Evaluation of the effectiveness of chronic antidepressant drug treatments in the hippocampal mitochondria—A proteomic study in an animal model of depression. Prog Neuropsychopharmacol Biol Psychiatry78: 51–60.
HamiltonM (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry23: 56–62.
14.
Herculano-HouzelS (2011) Scaling of brain metabolism with a fixed energy budget per neuron: Implications for neuronal activity, plasticity and evolution. PLoS One6: e17514.
15.
HirschfeldRM (2000) History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry61: 4–6.
16.
IshimaTFutamuraTOhgiY, et al. (2015) Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: A role for serotonin 5-HT1A and 5-HT2A receptors. Eur Neuropsychopharmacol25: 505–511.
17.
IwamotoKBundoMKatoT (2005) Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet14: 241–253.
18.
KatoMShiosakaiMKuwaharaK, et al. (2024) Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: A phase 2/3, randomized, double-blind (BLESS) study. Psychiatry Clin Neurosci78: 113–122.
19.
LiNFlanaganBAEdmandsS (2024) The role of mitochondria in sex- and age-specific gene expression in a species without sex chromosomes. Proc Natl Acad Sci U S A121: e2321267121.
20.
LivakKJSchmittgenTD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods25: 402–408.
21.
LoveMIHuberWAndersS (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol15: 550.
22.
MaMRenQYangC, et al. (2016) Adjunctive treatment of brexpiprazole with fluoxetine shows a rapid antidepressant effect in social defeat stress model: Role of BDNF-TrkB signaling. Sci Rep6: 39209.
23.
MaMRenQYangC, et al. (2017) Antidepressant effects of combination of brexpiprazole and fluoxetine on depression-like behavior and dendritic changes in mice after inflammation. Psychopharmacology (Berl)234: 525–533.
24.
MaedaKSuginoHAkazawaH, et al. (2014) Brexpiprazole I: In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther350: 589–604.
25.
ManjiHKatoTDi ProsperoNA, et al. (2012) Impaired mitochondrial function in psychiatric disorders. Nat Rev Neurosci13: 293–307.
26.
Martins-de-SouzaDGuestPCHarrisLW, et al. (2012) Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. Transl Psychiatry2: e87.
27.
McIntyreRSAlsuwaidanMBauneBT, et al. (2023) Treatment-resistant depression: Definition, prevalence, detection, management, and investigational interventions. World Psychiatry22: 394–412.
MrazekDAHornbergerJCAltarCA, et al. (2014) A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. Psychiatr Serv65: 977–987.
30.
NelsonJCPikalovABermanRM (2008) Augmentation treatment in major depressive disorder: Focus on aripiprazole. Neuropsychiatr Dis Treat4: 937–948.
31.
NunezNAJosephBPahwaM, et al. (2022) Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis. J Affect Disord302: 385–400.
32.
ParikhNBRobinsonDMClaytonAH (2017) Clinical role of brexpiprazole in depression and schizophrenia. Ther Clin Risk Manag13: 299–306.
33.
RezinGTAmboniGZugnoAI, et al. (2009) Mitochondrial dysfunction and psychiatric disorders. Neurochem Res34: 1021–1029.
34.
RossmanithWFreilingerMRokaJ, et al. (2008) Isolated cytochrome c oxidase deficiency as a cause of MELAS. J Med Genet45: 117–121.
35.
ShannonPMarkielAOzierO, et al. (2003) Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res13: 2498–2504.
36.
StrawbridgeRCarterBMarwoodL, et al. (2019) Augmentation therapies for treatment-resistant depression: Systematic review and meta-analysis. Br J Psychiatry214: 42–51.
37.
SuzukiSYamamotoMTogashiK, et al. (2019) In vitro and in vivo anti-tumor effects of brexpiprazole, a newly-developed serotonin-dopamine activity modulator with an improved safety profile. Oncotarget10: 3547–3558.
38.
ThaseME (2002) What role do atypical antipsychotic drugs have in treatment-resistant depression?J Clin Psychiatry63: 95–103.
39.
VazquezGHBahjiAUndurragaJ, et al. (2021) Efficacy and tolerability of combination treatments for major depression: Antidepressants plus second-generation antipsychotics versus esketamine versus lithium. J Psychopharmacol35: 890–900.
40.
WangKHuangSFuD, et al. (2024) The neurobiological mechanisms and therapeutic prospect of extracellular ATP in depression. CNS Neurosci Ther30: e14536.
41.
WeissCWeillerEBakerRA, et al. (2018) The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: An analysis of short-term and long-term studies. Int Clin Psychopharmacol33: 255–260.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
